Advanced glycation end-products induce calpain-mediated degradation of ezrin

FEBS Journal

Volumn 279, Issue 17, 2012, Pages 3240-3250

  McRobert, Elizabeth Anne ^a   Young, Andrea N ^a   Bach, Leon A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

advanced glycation end products; diabetes; ezrin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CALCIUM ION; CALPAIN; CALPASTATIN; CHELATING AGENT; EZRIN; GLUCOSE; MOESIN; RADIXIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL ACTIVATION; CELL STRAIN; CONTROLLED STUDY; IN VITRO STUDY; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANIMALS; CALPAIN; CATTLE; CELL LINE; CYTOSKELETAL PROTEINS; EPITHELIAL CELLS; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY TUBULES; PHOSPHORYLATION; PROTEOLYSIS;

BOVINAE;

EID: 84865255494     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08710.x     Document Type: Article

References (61)

1. Jerums G, Panagiotopoulos S, Forbes JM, Osicka TM, &, Cooper ME, (2003) Evolving concepts in advanced glycation, diabetic nephropathy and diabetic vascular disease. Arch Biochem Biophys 419, 55-62.
2. Forbes JM, Soldatos G, &, Thomas MC, (2005) Below the radar: advanced glycation end products that detour 'around the side'. Clin Biochem Rev 26, 123-134.
3. Zhang Q, Ames JM, Smith RD, Baynes JW, &, Metz TO, (2009) A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 8, 754-769.
4. Neeper M, Schmidt A-M, Brett J, Yan SD, Wang F, Pan Y-CE, Elliston K, Stern D, &, Shaw A, (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998-15004.
5. Goh S, &, Cooper ME, (2008) The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93, 1143-1152.
6. Ahmed N, &, Thornalley PJ, (2007) Advanced glycation endproducts: what is their relevance to diabetic complications? Diabetes Obes Metab 9, 233-245.
7. McRobert EA, Gallicchio M, Jerums G, Cooper ME, &, Bach LA, (2003) The amino terminal domains of ERM proteins bind advanced glycation endproducts: an interaction that may play a role in the development of diabetic complications. J Biol Chem 278, 25783-25789.
8. McClatchey AI, &, Fehon RG, (2009) Merlin and the ERM proteins-regulators of receptor distribution and signalling at the cell cortex. Trends Cell Biol 19, 198-206.
9. Niggli V, &, Rossy J, (2008) Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 40, 344-349.
10. McRobert EA, Tikoo A, Cooper ME, &, Bach LA, (2008) Localization of the ezrin binding epitope for advanced glycation endproducts. Int J Biochem Cell Biol 40, 1570-1580.
11. Bretscher A, Edwards K, &, Fehon RG, (2002) ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3, 586-599.
12. Gallicchio MA, McRobert EA, Tikoo A, Cooper ME, &, Bach LA, (2006) Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. J Am Soc Nephrol 17, 414-421.
13. Kaul SC, Kawai R, Nomura H, Mitsui Y, Reddel RR, &, Wadha R, (1999) Identification of a 55-kDa ezrin-related protein that induces cytoskeletal changes and localizes to the nucleolus. Exp Cell Res 250, 51-61.
14. Barret C, Roy C, Montcourrier P, Mangeat P, &, Niggli V, (2000) Mutagenesis of the phosphatidyl 4,5-biphosphate (PIP2) binding site in the NH2-terminal domain of ezrin correlates with its altered cellular distribution. J Cell Biol 151, 1067-1080.
15. Yao X, Thibodeau A, &, Forte JG, (1993) Ezrin-calpain 1 interactions in gastric parietal cells. Am J Physiol 265, C36-C46.
16. Suzuki K, Hata S, Kawabata Y, &, Sorimachi H, (2004) Structure, activation, and biology of calpain. Diabetes 53, S12-S18.
17. Franco JS, &, Huttenlocher A, (2005) Regulating cell migration: calpains make the cut. J Cell Sci 118, 3829-3838.
18. Shuster CB, &, Herman IM, (1995) Indirect association of ezrin with F-actin: isoform specificity and calcium sensitivity. J Cell Biol 128, 837-848.
19. Cortes P, Mendez M, Riser BL, Guerin CJ, Rodriguez-Barnero A, Hassett C, &, Yee J, (2000) F-actin fiber distribution in glomerular cells: structural and functional implications. Kidney Int 58, 2452-2461.
20. Zhou X, Hurst RD, D T, &, Whiteside C, (1995) High glucose alters actin assembly in glomerular mesangial and epithelial cells. Lab Invest 73, 372-383.
21. Kim EK, Geroski DH, Holley GP, Urken SI, &, Edelhauser HF, (1992) Corneal endothelial cytoskeletal changes in F-actin with aging, diabetes and after cytochalasin exposure. Am J Ophthalmol 114, 329-335.
22. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert EA, Thallas-Bonke V, Atkins RC, Osicka TM, Jerums G, &, Cooper ME, (2001) Advanced glycation endproducts cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation endproducts (RAGE). J Clin Invest 108, 1853-1863.
23. Gilbert RE, &, Cooper ME, (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury. Kidney Int 56, 1627-1637.
24. Ostalska-Nowicka D, Zachwieja J, Nowicki N, Kaczmarek E, Siwinska A, &, Witt M, (2006) Ezrin-a useful factor in the prognosis of nephrotic syndrome in children: an immunohistochemical approach. J Clin Pathol 59, 916-920.
25. Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP, Placha G, Canani LH, Bochenski J, et al. (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes, 58, 1403-1410.
26. Lopez JP, Turner JR, &, Philipson LH, (2010) Glucose-induced ERM protein activation and translocation regulates insulin secretion. Am J Physiol Endocrinol Metab 299, E772-E785.
27. Koga M, &, Kasayama S, (2010) Clinical impact of glycated albumin as another glycaemic control marker. Endocrine J 57, 751-762.
28. Paroni R, Ceriotti F, Galanello R, Battista Leoni G, Panico A, Scurati E, Paleari R, Chemello L, Quaino L, Scaldaferri L, et al. (2007) Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 40, 1398-1405.
29. Rondeau P, &, Bourdon E, (2011) The glycation of albumin: structural and functional impacts. Biochimie 93, 645-658.
30. Hirokawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner TH, Mashima H, Schwarz PEH, et al. (2000) Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 26, 163-175.
31. Harris F, Biswas S, Singh J, Dennison S, &, Phoenix DA, (2006) Calpains and their multiple roles in diabetes mellitus. Ann N Y Acad Sci 1084, 452-480.
32. Marshall C, Hitman GA, Partridge CJ, Clark A, Ma H, Shearer TR, &, Turner MD, (2005) Evidence that an isoform of calpain-10 is a regulator of exocytosis in pancreatic β-cells. Mol Endocrinol 19, 213-224.
33. Tompa P, Mucsi Z, Orosz G, &, Friedrich P, (2002) Calpastatin subdomains A and C are activators of calpain. J Biol Chem 277, 9022-9026.
34. Stalker TJ, Gong Y, &, Scalia R, (2005) The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 54, 1132-1140.
35. Sreenan SK, Zhou Y-P, Otani K, Hansen PA, Currie KPM, Pan C-Y, Lee J-P, Ostrega DM, Pugh W, Horikawa Y, et al. (2001) Calpains play a role in insulin secretion and action. Diabetes 50, 2013-2020.
36. Harwood SM, Allen DA, Raftery MJ, &, Yaqoob MM, (2007) High glucose initiates calpain-induced necrosis before apoptosis in LLLC-PK1 cells. Kidney Int 71, 655-663.
37. Dong Y, Wu Y, Wu M, Wang SC, Zhang J, Xie Z, Xu J, Song P, Wilson K, Zhao Z, et al. (2009) Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. J Cell Mol Med 13, 2899-2910.
38. Banoczi Z, Alexa A, Farkas A, Friedrich P, &, Hudecz F, (2008) Novel cell-penetrating calpain substrate. Bioconjug Chem 19, 1375-1381.
39. Massry SG, &, Smorgorzewski M, (1997) Role of elevated cystolic calcium in the pathogenesis of complications in diabetes mellitus. Miner Electrolyte Metab 23, 253-260.
40. Jan CR, Chen CH, Wang SC, &, Kuo SY, (2005) Effect of methylglyoxal on intracellular calcium levels and viability in renal tubular cells. Cell Signal 17, 847-855.
41. Matihagela K, &, Taub M, (2006) Involvement of EP1 and EP2 receptors in the regulation of the Na, K-ATPase by prostaglandins in MDCK cells. Prostaglandins Other Lipid Mediat 79, 101-113.
42. Tompa P, Buzder-Lantos P, Tantos A, Farkas A, Szilagyi A, Banoczi Z, Hudecz F, &, Friedrich P, (2004) On the sequential determinants of calpain cleavage. J Biol Chem 79, 20775-20785.
43. Kishore R, Qin G, Luedemann C, Bord E, Hanley A, Silver M, Gavin M, Goukassain D, &, Losordo DW, (2005) The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-α-induced transcriptional repression of cyclin A. J Clin Invest 115, 1785-1796.
44. Wang H, Guo Z, Wu F, Long F, Cao X, Liu B, Zhu Z, &, Yao X, (2005) PKA-mediated protein phosphorylation protects ezrin from calpain I cleavage. Biochem Biophys Res Commun 333, 496-501.
45. Sprague CR, Fraley TS, Jang HS, Lal S, &, Greenwood JA, (2008) Phosphoinositide binding to the substrate regulates susceptibility to proteolysis by calpain. J Biol Chem 283, 9217-9223.
46. Fievet BT, Louvard D, &, Arpin M, (2006) ERM proteins in epithelial cell organization and functions. Biochem Biophys Acta 1773, 653-660.
47. Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR, Abrahamsen H, Herberg FW, Carpen O, &, Tasken K, (2007) Inhibition of T cell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type 1 by the A-kinase anchoring protein ezrin. J Immunol 179, 5159-5168.
48. Nakamura F, Huang K, Pestonjamasp E, Luna J, &, Furthmayr H, (1999) Regulation of F-actin binding to platelet moesin in vitro by both phosphorylation of threonine 558 and phosphatidylinositides. Mol Biol Cell 10, 2669-2685.
49. Wakayama Y, Miura K, &, Mochizuki N, (2011) EphrinA1-EphA2 signal induces compaction and polarization of MDCK kidney cells by inactivating ezrin through negative regulation of RhoA. J Biol Chem 268, 44243-44253.
50. Batchelor CL, Woodward AM, &, Crouch DH, (2004) Nuclear ERM (ezrin, radixin, moesin) proteins: regulation by cell density and nuclear import. Exp Cell Res 296, 208-222.
51. Guo X, Wang L, Chen B, Li Q, Wang J, Zhao M, Zhu P, Huang X, &, Huang Q, (2009) ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol 297, H238-H246.
52. Li Q, Liu H, Du J, Chen B, Li Q, Guo X, Huang X, &, Huang Q, (2011) Advanced glycation end products induce moesin phosphorylation in murine brain endothelium. Brain Res 1373, 7-15.
53. Berryman M, Franck Z, &, Bretscher A, (1993) Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J Cell Sci 105, 1025-1043.
54. Ilani T, Khanna C, Zhou M, Veenstra TD, &, Bretscher A, (2007) Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin. J Cell Biol 179, 733-746.
55. Shaffer MH, Dupree RS, Zhu P, Saotome I, Schmidt RF, McClatchey AI, Freedman BD, &, Burkhardt JK, (2009) Ezrin and moesin function together to promote T cell activation. J Immunol 182, 1021-1032.
56. +-glucose cotransport. Proc Natl Acad Sci USA 101, 9485-9490.
57. Crepaldi T, Gautreau A, Comoglio PM, Louvard D, &, Arpin M, (1997) Ezrin is an effector of HGF-mediated migration and morphogenesis in epithelial cells. J Cell Biol 138, 423-434.
58. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345, 861-869.
59. Kamal F, Yanakieva-Georgieva N, Piao H, Morioka T, &, Oite T, (2010) Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity. Nephron Exp Nephrol 115, e69-e79.
60. Di Christofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A, Petrozza V, &, Della Rocca C, (2010) Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol 23, 1012-1020.
61. Noren NK, Niessen CM, Gumbiner BM, &, Burridge K, (2001) Cadherin engagement regulates Rho family GTPases. J Biol Chem 276, 33305-33308.